Cardiac tissue engineering approaches can deliver large numbers of cells to the damaged myocardium and have thus increasingly been considered as a possible curative treatment to counteract the high prevalence of progressive heart failure after myocardial infarction (MI). Optimal scaffold architecture and mechanical and chemical properties, as well as immune-and bio-compatibility, need to be addressed. We demonstrated that radio-frequency plasma surface functionalized electrospun poly (e-caprolactone) (PCL) fibres provide a suitable matrix for bone-marrow-derived mesenchymal stem cell (MSC) cardiac implantation. Using a rat model of chronic MI, we showed that MSC-seeded plasma-coated PCL grafts stabilized cardiac function and attenuated dilatation. Significant relative decreases of 13% of the ejection fraction (EF) and 15% of the fractional shortening (FS) were observed in sham treated animals; respective decreases of 20% and 25% were measured 4 weeks after acellular patch implantation, whereas a steadied function was observed 4 weeks after MSC-patch implantation (relative decreases of 6% for both EF and FS).
Introduction
Despite significant improvements in medical and surgical interventions, cardiovascular diseases remain the major cause of death in industrialized countries. Consequently, the urgent need for alternative therapies has been addressed, including strategies focusing on the possible reverse remodelling of the cardiac structure and recovery of the contractile function [1] . During the past decade, myocardial stem cell injection has provided encouraging clinical outcomes and might become an accepted therapy [2] . However, the ischemic myocardium represents a hostile environment and successful clinical implementation of cell therapy is thus hampered by several challenges, including poor survival of injected cells and their limited retention and engraftment [3] [4] [5] .
The use of biomaterials to engineer exogenous micro-tissues for cell delivery may be an attractive strategy to promote reproducible prolonged cell survival and retention [6, 7] . Polymeric matrices aim at providing a favorable environment for ex vivo cell adhesion and growth, and for facilitated implantation onto the ischemic myocardium [4, [8] [9] [10] [11] [12] [13] .
However, the pertinence of acellular patches for cardiac function improvement has been demonstrated [14, 15] . Epicardial implantation of acellular patches after myocardial injury resulted in left ventricular (LV) function improvement and limited progression of LV dilation. Therefore, the relevance of cells implanted together with a scaffold remains an open question. The systematic comparison of therapeutic efficacy of the scaffold alone or with cells is of paramount importance to provide specific answers for any new patch.
Nevertheless, the choice of material, the consequential role of cell-matrix interactions and the vascularization of the biograft are major aspects to consider. Recent studies have highlighted the suitability of synthetic electrospun-based scaffolds that can be fine-tuned, with respect to their biocompatibility and their architectural, mechanical and chemical properties, in order to provide an optimal microenvironment for cell growth [16, 17] . Electrospun fibres have been successfully used for the engineering of soft tissues [18] or cardiac valves [19] . Their application in myocardial tissue engineering is, however, still in its infancy. In vitro evaluations underpinned the suitability of electrospun membranes for cardiomyocyte guidance and differentiation as well as maintenance of their contractile function [20] [21] [22] . The fibrous, anisotropic architecture of electrospun scaffolds compared to solid substrates proved superior for cardiomyocyte maturation and, in particular, cell infiltration and multi-layered tissue formation [23] [24] [25] .
Poly(e-caprolactone) (PCL), a material approved by the US Food and Drug Administration, holds great potential for successful implementation due to its good immune-tolerance, high availability and practicable processability by electrospinning [26, 27] . Previous studies highlighted the versatility of electrospun PCL to create synchronously beating multi-layered cardiac constructs [28, 29] . However, in vivo evaluations of the efficiency of cell-seeded electrospunbased matrices applied onto infarcted myocardium are still lacking.
Due to the strongly hydrophobic nature of electrospun PCL matrices, an enhanced biological interface, holding particular importance in cell-matrix interactions, must be generated by surface functionalization. Several methods, among them blending of synthetic polymers with ECM proteins, are known to induce enhanced cell adhesion [30, 31] . With respect to clinical application, naturally occurring proteins raise concerns due to their xenogenic origin, potential contamination and low availability at high costs [32] . To this end, the substitution of proteins or peptides by functional groups generated in wet-chemical or plasma-based processes presents a versatile advantage. Adapted process parameters during plasma polymerization allow for tissue specific functionalities and the formation of stable surface coatings [16, 33, 34] .
In the current study, we aimed at developing a new plasmacoated, parallel-oriented electrospun PCL substrate that structurally and chemically provides adhesion sites for cellular attachment, is immune-tolerant and guarantees scaling up possibilities for translational research. The designed cardiac patch, acellular vs. seeded with mesenchymal stem cells (MSCs), was evaluated in a rodent model of chronic myocardial infarction (MI). We provide evidence that the designed matrices provide a safe and efficient substrate for MSC growth and delivery thereof to the ischemic heart. We furthermore report that this treatment induces improved performance of infarcted hearts with attenuation of LV dilatation and stabilized cardiac function.
Materials and methods

Substrate production and characterization
Fibrous substrates were produced and characterized as previously established in our group [16] . In short, a 15% w/v PCL (Sigma-Aldrich, Buchs, Switzerland) spinning solution was prepared by dissolving PCL in a mixture of chloroform/methanol (9:1) (Sigma-Aldrich, Buchs, Switzerland). Solutions were processed by electrospinning at a flow rate of 30 ll min À1 , with an applied field strength of 1 kV cm
À1
, and collected on a rotating drum ($1000 rpm).
Electrospun patches were functionalized using a radio-frequency (RF) plasma process. An oxygen functional hydrocarbon layer (a-C:H:O) was deposited according to previously established protocols [35] . Briefly, 4 standard cubic centimetre per minute (sccm) ethene (C 2 H 4 ), 24 sccm carbon dioxide (CO 2 ) and 50 sccm argon (Ar) were introduced into a symmetric reactor chamber. All gases were of 99.9 vol.% purity and provided by Carbagas, Güm-ligen, Switzerland. RF power input was set to 34 W at a chamber pressure of 0.1 mbar and plasma exposure time of 15 min. Surface functionalization was characterized by X-ray photoelectron spectroscopy (XPS) analysis as previously reported [16] .
Wettability was assessed by static contact angle measurements (Krüss GmbH, Hamburg, Germany). A drop of 10 ll distilled water was deposited on the fibrous substrates. Measurements were repeated three times. Substrate morphology and fibre diameter (based on 100 individual measurements, Image J, free download under http://rsbweb.nih.gov/ij/) were characterized by scanning electron microscopy (SEM). Prior to imaging, substrates were gold-sputtered (Polaron Equipment, SEM coating Unit E5100, Kontron AG, Switzerland; 5 mA, 1 mbar, 7 min) and recorded on a Hitachi S-4800 (Hitachi High-Technologies, US, Illinois, USA) at an accelerating voltage of 2 kV and 10 lA current flow.
Elasticity (E modulus) of the patches and yield strength were assessed by stress-strain measurements on an MTS 858 Mini Bionix (Bionix systems, MTS Eden Prairie, USA) equipped with a 25 N load cell and a displacement rate of 0.15 mm s
. Substrates were pre-incubated in culture medium or seeded with MSCs, respectively, prior to measurements.
In vitro evaluation
MSC isolation and characterization
All experiments were carried out with MSCs obtained from rat bone marrow. Briefly, the bone marrow from the femur and tibia of 5 male Lewis rats (200 g) was flushed with sterile phosphate buffered saline (PBS; Spitalpharmazie, Inselspital Bern, Switzerland), centrifuged and resuspended in red blood cell lysis buffer (Gentra Systems Inc.; Minneapolis, USA). After 10 min incubation, samples were centrifuged, resuspended in fresh medium and seeded in culture flasks. MSCs were selected upon adherence and medium was removed after 2 days. The medium was then transferred into a new flask in order to further collect adherent cells.
Cell culture was performed under standard conditions on tissue treated polystyrene (TCPS; TPP Omnilab, Mettmenstetten, Switzerland and BD, Biosciences, San José, USA), at 37°C and 5% CO 2 in a humidified incubator (Thermo Forma, Model 371, Thermo Fisher Scientific, Waltham, USA). MSCs were expanded in growth medium (Dulbecco's modified Eagle Medium, Gibco, Invitrogen, Carlsbad, USA) supplemented with 20% fetal bovine serum (FBS; PAA clone, Connectorate AG, Dietikon, Switzerland) and 1.25% penicillin/ streptomycin solution (P/S; 100 lg ml
À1
, Gibco, Invitrogen, Carlsbad, USA). MSCs were maintained in culture and expanded for 1 week. Medium was changed every second day. Accutase was used to detach the cells prior to culture on substrates for 1 week.
MSCs were characterized by fluorescence activated cell sorting (FACS; FACScan, BD, Biosciences, San José, USA) using PE-labelled anti CD90, FITC-labelled anti CD45 and PE-labelled anti CD31 (all BD, Biosciences, San José, USA SEM was carried out to investigate cell morphology. Prior to imaging, constructs were fixed in 4% formaldehyde (Institute of Pathology, University Hospital Bern, Switzerland) and dehydrated in an ascending ethanol series and dried in hexamethyldisiloxane (Sigma-Aldrich, Buchs, Switzerland). Constructs were gold-sputtered and micrographs were acquired on a Hitachi S-4800 at 2 kV acceleration voltage and 10 lA current flow.
In vivo evaluation
All animals received humane care in compliance with the European Convention on Animal Care.
Surgical procedures were performed in accordance with the Swiss Animal Protection Law after permission was obtained from the State Veterinary Office, Bern, approved by the Swiss Federal Veterinary Office, Switzerland (BE 40/10). All surgical interventions were performed under isofluorane anesthesia. Efforts were made to diminish animal suffering; in particular, all animals received subcutaneous injection of 0.1 mg kg À1 Temgesic (Buprenorphine,
mg ml
À1
; ESSEX Chemie, Luzern, Switzerland) post-surgery.
Model of MI
As previously reported [4] , cardiac patch evaluation was carried out in an established surgical model of MI. 41 female Lewis rats (Janvier, Le Genest, France), weighing 230 g were anesthetized with isoflurane and oxygen (5% for induction and 2.5% for maintenance). Rats were placed on a warming pad of 37°C to avoid hypothermia during anesthesia and ventilated with 80 cycles min À1 (14-G IV cannula, Abbocath, Abbott, Sligo, Ireland; Small Animal Ventilator 683 Harvard Apparatus, Inc., Holliston, USA). For surgical induction of an MI, hearts were accessed through a left thoracotomy between the fourth and fifth interstitial space. After opening the pericardium, a permanent ligation of the left anterior descending coronary artery was performed (7/0 polypropylene suture, Ethicon, Inc., Somerville, USA), resulting in permanent blood restriction. 2 weeks post-infarction, animals with an assessed ejection fraction between 30% and 65% were randomized into three treatment groups, receiving either MSC-seeded cardiac patches (MSCPs, n = 11), MSC-free cardiac patches (CPs, n = 11) or a sham operation (sham, n = 14). Treatment was applied via a second thoracotomy between the fifth and sixth interstitial space.
MSCPs or CPs were glued (Tisseel Fibrin sealant, Baxter, Deerfield, USA) cell-side down onto the myocardium. Fiber orientation of the patch was parallel to the longitudinal axis of the heart, from apex to aorta. Sham treated rats underwent a second thoracotomy without any applied treatment.
Functional analysis
Echocardiograms were recorded 2 weeks post-MI (pre-treatment) and 6 weeks post-infarction (post-treatment) by a wellexperienced cardiologist in a blinded manner. Briefly, rats were anesthetized with 2.5% isoflurane and placed on the left lateral position. Echocardiographs were recorded using a 9-11 MHz linear array transducer system (AcusonSequoia, Siemens, Inc., Malvern, USA). LV M-mode measurements were performed to quantify internal diameters at systole and diastole and to calculate fractional shortening (FS) in percentage:
A two-dimensional (2-D) mode obtained from a long axis view was used to determine volume and ejection fraction (EF) using a biplane Simpson's method.
Histological analysis
Molecular mechanisms underlying repair of myocardial tissue were investigated immunohistologically. Infarct size, vascular density and immune response were assessed.
Hearts were excised and washed in PBS. A transversal cut was placed 5 mm from the apex. The lower part was embedded in optimal cutting temperature medium (OCT; Tissue Tek, Sakura, Alphen aan den Rijn, The Netherlands) and frozen over 2 methyl-butan vapour (Sigma-Aldrich, Buchs, Switzerland), cooled with liquid nitrogen (Carbagas, Gümligen, Switzerland). OCT embedded hearts were stored at À80°C.
Subsequently, hearts were cryosectioned on a Leica CM 3050S cryostat (Leica Biosystems GmbH, Nussloch, Germany) at a slice thickness of 8 lm.
Fibrotic tissue was assessed based on Goldner staining. Briefly, cryosectioned hearts were thawed and air-dried and fixation was carried out in Bouin fixation solution overnight (glacial acetic acid, 36% formalin and picric acid; all Sigma-Aldrich, Buchs, Switzerland), followed by incubation in Weigert's Hematoxyline (Merck AG, Zug, Switzerland), Acid Fuchsin-Ponceau (Sigma-Aldrich, Buchs, Switzerland), Phosophomolybden acid Orange G (Merck AG, Zug Switzerland and Sigma-Aldrich, Buchs, Switzerland) and Lichtgrün (Sigma-Aldrich, Buchs, Switzerland).
Samples were dehydrated in an ascending ethanol series and mounted with Eukitt (EM Sciences, Hatfield, USA). Images were acquired on a Nikon Eclipse-2000 light microscopy (Nikon, Tokyo, Japan). The LV was manually traced on the digital image. The LV was selected and the right ventricle excluded from the picture. Using the colour recognition option of the software (Bersoft Image Analysis, Bersoft Technology and Software, Lunenburg, Canada), we obtained the area of the LV myocardium (red), the area of the LV cavity (white) and the area of the infarct (green). We also obtained the septum and scar thickness by averaging three distances measured from each wall. Relative scar thickness was calculated as scar thickness divided by septum thickness. Whole LV area was calculated by adding the area of the LV myocardium and LV cavity. Expansion index was calculated as follows [37] : expansion index ¼ LV cavity area=whole LV area relative scar thickness ð2Þ
Whereas the percentage infarct size was calculated as infarct sizeð%Þ ¼ infarct area LV myocardium area Â 100 ð3Þ
Measurements were accomplished and averaged based on nine cryosections of n = 9 (MSCP), n = 11 (CP) and n = 11 (sham) respectively [38] . Immunohistological stainings were assessed on thawed, air dried, fixed (4% formaldehyde) and permeabilized (0.2% triton X-100 in PBS Sigma-Aldrich, Buchs, Switzerland) cryosections. Nonspecific sites were blocked in 3% bovine serum albumin solution (BSA; Sigma-Aldrich, Buchs, Switzerland) prior to primary antibody incubation, followed by fluorescently labelled secondary antibody incubation. Quantitative histological analysis was accomplished on three cuts of 8 lm thickness per sample and expressed as mean ± SD.
Vessel formation was assessed by von Willebrand factor (vWf) staining (anti vWf antibody, abcam, Cambridge) [39] . Constructs were counterstained with Hoechst (No 33258; Invitrogen, Molecular Probes, Carlsbad, USA) and mounted with Glycergel (Dako, USA). Vessels were counted manually based on light microscopy images and reported as number of vessels mm
À2
. Measurements were accomplished and averaged based on six cryosections of n = 3 animals per group.
Inflammatory response was assessed based on CD68 staining for macrophages [40] . Constructs were incubated with anti-CD68 antibody (MCA341, Abd Serotec, Oxford, UK), followed by fluorescently labelled antibody (Alexa 555 conjugated antibody, Invitrogen, Carlsbad, USA) and counterstaining with Hoechst. CD68 (+) cells were automatically counted with NIS elements software (Nikon, Tokyo, Japan) based on fluorescent images, colour and size recognition in a blinded manner. Results are reported as number of CD68 (+) cells mm
. Measurements were accomplished and averaged based on three cryosections of n = 3 animals per group.
Chromosome Y tracking
Upon heart excision, a distal section containing a part of the infarcted region and the biograft (MSCP, n = 3) or the infarcted region and the patch (CP, n = 4) was embedded in RNA-later (Qiagen AG, Basel, Switzerland) and gradually frozen to À80°C. Chromosome Y analysis (SRY1 gene tracking) was performed by Microsynth, Balgach, Switzerland. Genomic DNA extraction was accomplished with a Qiamp-Kit (Qiagen AG, Basel, Switzerland), followed by reverse transcription polymerase chain reaction (RT-PCR) (Taqman-Universal Mastermix, Applied Biosystems). Probe, forward and reverse primer were respectively CTGCTCCTACC TATGCCAACACTCC (probe), CCTGTGATAGGTAATCTCATG (forward) and CACACTACACATCCTTACAC (reverse).
Statistical analysis
Results are presented as mean ± standard deviation. Differences between pre-and post-treatment (data of echocardiography) were assessed by a non-parametric paired signed-rank Wilcoxon test, values of histological quantification by a Kruskal-Wallis test (SPSS for Windows; version 17.0; SPSS Inc, Chicago, USA). Values were accepted as significantly different for P < 0.05.
Results
Characterization and in vitro evaluation of plasma-coated electrospun substrates
To provide an adequate microenvironment for cell adhesion and growth, it is important to control the surface chemistry and architecture of the matrix. We processed PCL by electrospinning to produce fibres that displayed diameters of 3.3 ± 0.8 lm. By spinning onto a rotating collector, we obtained an anisotropic matrix of parallel oriented fibres (Fig. 1A) . The oxygen functional hydrocarbon coating (a-C:H:O), superimposed on the surface of the fibres by plasma polymerization, was validated by XPS analysis. The high CO 2 /C 2 H 4 ratio of 6:1 supports plasma chemical formation of oxygen-containing hydrocarbon species within the gas phase, showing rather low sticking probabilities [41] . Therefore, good penetration of the complex fibrous structure by the film-forming species is enabled, yielding a coating thickness of several nanometres on the fibres.
The composition of oxygen functional groups was confirmed and characterized by use of high resolution C1s spectra (Fig. 1C) showing an O/C ratio of $0.35 [35] . The high amount of ester groups (COOR) obtained indicates cross-linking of the ultrathin plasma polymer layer [42] .
We further evaluated the consequential modification in surface wettability and showed that oxygen-functionalized coatings greatly reduced the static water contact angle on the electrospun fibres from 114 ± 13°to complete wicking conditions. The corresponding drop absorption within 1 to 10 s confirmed the high hydrophilicity of plasma functionalized electrospun matrices.
Using a standardized procedure [36] , MSCs were seeded on the substrates and cultured for 7 days. MSCs spread on the surface of the matrix, following the parallel fibre orientation, forming a homogeneous layer (Fig. 1B) . MTT analysis confirmed MSC viability, indicated by intense blue staining (data not shown). DNA quantification revealed a number of 2 ± 0.9 Â 10 6 cells per patch, corresponding to a density of 1.33 Â 10 4 cells mm À2 .
In order to test the hypothesis that the matrix and the matrix seeded with cells would provide different mechanical support to the injured heart, we compared the mechanical properties of the cell-free CP to the MSCP, both pre-incubated in culture medium. E moduli were 18.3 ± 0.9 MPa and 16.1 ± 3.9 MPa for CP and MSCP, respectively. Representative stress-strain curves are displayed in Fig. 1D . Our data demonstrated that both patches presented identical mechanical properties in terms of elasticity and plasticity.
Implantation and in vivo evaluation of cardiac patches
Following in vitro evaluation, we implanted MSC seeded and cell-free patches in a rodent model of a chronic MI. MI was induced by permanent ligation of the left anterior descending artery (LAD).Two weeks post-MI, the patches were glued to the surface of the necrotic area. Animals received either an MSCP (n = 11) or a cell-free CP (n = 11). 14 rats served as control and received no treatment post-MI (sham group). In addition, hearts of three healthy animals were excised as control group (control). The mortality rate was 5%; animal death occurred after LAD ligation during the first surgery. All animals survived the second surgery and patch implantation.
Implantation of the cardiac patch was performed directly on beating hearts. The mechanical integrity of the patch and optimized handling allowed for safe and efficient fixation. A thin layer of Tisseel glue Ò and gentle positioning of the patch on the myocardium, followed by careful placing with forceps, guaranteed a full coverage and adhesion to the necrotic tissue ( Fig. 2A) . Only two animals were not included in the study due to technical difficulties during implantation; i.e. the patch was folded during implantation and was not correctly placed to the myocardium. Four weeks postimplantation, MSCPs or CPs were well adherent to the myocardium and presented minor adhesion to the surrounding tissue (Fig. 2C ).
MSC-seeded cardiac patches stabilized cardiac function and prevented LV dilatation
We used M mode and 2-D mode echocardiography to assess, respectively, fractional shortening (% FS) and ejection fraction (% EF), both pre-and post-treatment. Control animals without MI displayed EF and FS values of 74 ± 4% and 44 ± 3%, respectively. Echocardiography performed two weeks post-LAD ligation confirmed the presence of an established MI, as indicated by a reduced cardiac function (EF of 49 ± 9% and an FS of 22 ± 4%; P < 0.0001). 4 weeks later, as presented in Fig. 3 , cardiac function was further reduced in sham and CP-treated animals. As demonstrated in Fig. 3 , delta EF and delta FS (percentage point (pp) difference between postand pre-treatment) were À10 ± 9 pp (P = 0.006) and À6 ± 6 pp (P = 0.010) in CP treated animals; À7 ± 10 pp (P = 0.011) and À5 ± 6 pp (P = 0.010) in sham treated animals. In contrast, MSCP treatment induced a stabilization in cardiac function, represented by a delta EF of À4 ± 10 pp (P = 0.285) and a delta FS of À2 ± 7 pp (P = 0.182). These changes corresponded to the following relative percent decreases (calculated as (difference between post-and pre-treatment) Â 100/pre-treatment): respectively, a decrease of 13% of EF and 15% of FS in the sham group, 20% and 25%; in the CP group and 6% for both EF and FS in the MSCP group.
LV dimensions (diameter and volume) obtained by echocardiography for healthy animals were, respectively, 3.1 ± 0.3 mm and 0.10 ± 0.00 ml at the end of systole and 5.6 ± 0.2 mm and 0.41 ± 0.04 ml at the end of diastole. LAD ligation induced, after 2 weeks, an increase in LV diameter and volume at the end of systole (5.5 ± 0.8 mm and 0.40 ± 0.16 ml, respectively; P < 0.0001) and at the end of diastole (7.0 ± 1.3 mm and 0.83 ± 0.29 ml, respectively; P < 0.0001).
4 weeks post-treatment, diastolic and systolic diameters and volumes were further recorded. At the end of diastole, we measured significant increases in LV diameter in CP (+0.9 ± 1 mm, P = 0.02) and sham (+0.8 ± 0.9 mm, P = 0.006) treated animals (Fig. 4) . Conversely, we observed that LV diameter of MSCP treated animals remained statistically similar for pre-or post-treatment (+0.3 ± 0.8 mm, P = 0.212). In line, the LV end diastolic volume was significantly increased for CP or sham treated animals and stabilized in MSCP treated animals.
Regarding LV diameters measured at the end of systole, an increase of +1.3 ± 11 mm (P = 0.007) and +1.0 ± 0.9 mm (P = 0.003) was observed in CP and sham treated groups, respec- tively. A significant smaller (+0.4 ± 0.6 mm, P = 0.021) increase was observed in the MSCP group (Fig. 4) .
Histological evaluation of implanted patches
Vascularization of implants presents a necessary prerequisite to provide adequate nutrient and oxygen supply to the implanted cells. Macroscopic observations showed that cardiac patches were covered with a thin layer of connective tissue with visible vascularization (Fig. 2B) . Post-excision, we examined the number and density of vessels present within the patches by an anti-von Willebrand factor (vWf) staining, a marker of endothelial cells (Fig. 5) . The results revealed that the vessel density within the patch was comparable for both MSCP and CP (5 ± 0.5 and 5 ± 3 vessels mm À2 , respectively). Results are displayed in Table 1 . Induction of MI is associated with the stimulation of an inflammatory response, represented by the recruitment of macrophages within the ischemic area. We examined if cardiac patch treatment altered macrophage recruitment using anti-CD68 immunostaining, a macrophage surface marker. Results showed that CD68 (+) macrophages invaded the fibrotic area of hearts in all groups. In CP and MSCP treated animals, we measured a significantly higher number of CD68 (+) cells compared with sham treated animals (Fig. 6 ). On healthy, non-infarcted hearts that received patch treatment (no MI with CP), CD68 (+) macrophages were absent. . End systolic LV diameter was significantly elevated in all groups. End diastolic diameter was stabilized in MSCP treated animals, but significantly elevated in control groups. In line, LV volumes during systole were significantly increased in all groups, whereas LV volume during diastole was stabilized in MSCP treated animals ( ⁄ P < 0.05, ⁄⁄ P < 0.01, pre-vs. post-treatment).
Rapidly after MI and consequent inflammation, the recruitment of myofibroblasts induced the formation of a fibrotic area. We evaluated if the treatment affected the healing process and assessed, 6 weeks following the LAD ligation, the percentage of fibrotic area and the degree of infarct expansion. Characterization of the fibrotic area and the scar dimensions were performed by image analysis of Goldner stained cryosections (Fig. 7) . Fibrotic area, relative scar thickness and expansion index were statistically identical in each group (Table 2) .
MSC seeded matrices allowed cell retention at the site of the infarction
We evaluated the presence of implanted cells 4 weeks postimplantation. Sex-mismatched implantation of MSC and PCR analysis on myocardial biopsies from the necrotic area allowed for chromosome Y identification. The presence of implanted MSCs was proven by a normalized Ct value of SRY of 0.86 ± 0.76 in MSCP treated animals. In the CP group, detection of chromosome Y was below the detection limit and confirmed the absence of male MSCs as expected.
Discussion
In the present study, we demonstrated, and to the best of our knowledge for the first time, that plasma-functionalized electrospun PCL matrices represent a rapid, safe and efficient approach for epicardial delivery of MSC.
Myocardial cell therapy aims at counteracting MI consequences such as ventricular dilatation and remodelling by promoting endogenous tissue repair and regeneration. Up to now, a series of research work has demonstrated positive effects of cell therapy on reduction of cardiomyocyte necrosis, induction of angiogenesis and activation of host stem cell recruitment via the secretion of paracrine factors [43] . The clinical benefit of intramyocardial injection of autologous MSCs has also been increasingly reported [5] . However, issues such as the optimal mode of cell delivery remain open and represent important challenges to consider in order to improve outcomes of cardiac cell therapy. Tissue engineering approaches have gained increasing interest for controlled delivery of cells. In particular, it allows monitoring cell adhesion to the scaffold as well as implanting cells to defined and extended areas of the damage myocardium.
Cell adhesion and cell-biomaterial interaction is governed by material surface properties. We hereby provide evidence that incorporating oxygen functional groups to the matrix provided an adequate substrate for MSC culture. Accordingly, we have previously reported that oxygen functional groups improve the biointerface by reducing the scaffold hydrophobicity and enhancing cell adhesion of skeletal muscle cells (C2C12) and cardiogenic embryonic stem cells [16, 44] .
Furthermore, we showed that our matrix allowed the retention of MSCs four weeks post-epicardial implantation. Using RT-PCR, we identified the presence of implanted male MSCs in biopsies Scar tissue 12 ± 1 17 ± 8 9 ± 2 Scaffold 5 ± 0.5 5 ± 3 Non-ischemic tissue 9 ± 3 9 ± 4 9 ± 2 10 ± 1 Vessels were counted manually based on light microscopy images.
composed of myocardium and implanted construct. Furthermore, this highly sensitive and specific technique confirmed the absence of Y chromosomes in the CP group. Nevertheless, quantification of surviving cells and their localization was not aimed in the current study and would require other specific approaches. Biocompatibility of the constructs can be modified by chemical and architectural properties that modulate immune response and macrophage invasion. It has been reported that hydrophilic implants were generally better tolerated by the host [45] . Moreover, fibrous, parallel oriented substrates were shown to reduce pro-inflammatory cytokine production when compared to 2-D films or randomly oriented fibres of the same material [46] . In our current study, we demonstrated that a plasma-coated, hydrophilic cardiac patch presenting parallel oriented fibres does not trigger macrophage invasion when implanted on healthy rat hearts, revealing thus the immune-tolerance of this patch. In our MI model, however, macrophage invasion was significantly increased in both MSCP and CP treated animals as compared to sham treated animals. This indicates that in response to MI, the immune response initially triggered by the ischemic injury was modulated by MSCP or CP implantation. Additionally, other parameters such as fibrotic area and scar expansion remained similar in all the groups. Taking together, our results suggest that our scaffold may play an active role in post-MI inflammation process. However, this inflammation response persisting for 4 weeks post-MI in treated groups was not associated with increased fibrosis. Therefore, further investigation will be necessary to define the role of this prolonged inflammation in the balance between reparative vs. reactive fibrosis of the myocardium.
Infarction development is largely variable between animals; we therefore compared cardiac function of pre-and post-treatment to evaluate therapeutic efficacy. This design setting is similar to the clinical reality and inter-patient variability. We demonstrated a stabilization of the heart function in MSCP treated animals compared to a loss in cardiac function in untreated animals. A stabilized cardiac function will limit the progression toward heart failure. In addition, LV dilatation usually occurred during remodelling of the left ventricle after MI. It represents a strong prognostic determinant and is closely related to the incidence of heart failure. We provide evidence of attenuation of post-MI dilatation following Figure 6 . Macrophage invasion was quantified based on anti CD68 staining (green, nuclei stained in blue). ''Control'' indicates animals without MI where a cell-free cardiac patch was applied. An increased number of CD68 (+) cells was found in the scar tissue of MSCP or CP treated animals, compared with sham operated animals ( ⁄ P < 0.05). No macrophage invasion was found on healthy hearts that received CP implantation. Green stainings in the control group are artifacts and do not co-localize with nuclei staining and were therefore not identified as CD68 (+) cells. MI: picture taken in the area of myocardial infarction. P: picture taken from the implanted CP or MSCP. Macrophages were predominantly located within the infarcted tissue, not invading the implant. Scale bar: 10 lm.
MSCP treatment. In contrast, remodelling after MI progressively leads to systolic expansion and cardiac dilatation as expected in the sham group. Similarly, increased LV diameter and volume, during both systole and diastole, clearly indicates a progressive cardiac dilatation after CP treatment. Therefore, we demonstrated that a plasma-functionalized electrospun matrix alone has no therapeutic effect. Our results suggest that the implanted matrix alone does not provide a sufficient mechanical constrain that may stabilize the heart function. In agreement, a recent study by Rane et al. [47] demonstrated that a passive myocardium structure reinforcement after synthetic polymer injection is insufficient for cardiac function stabilization. Both MSCP and CP presented similar mechanical properties; accordingly the mechanical girding effect could be excluded to explain the observed therapeutic effect following MSCP treatment. The observed functional benefit corroborates previous studies including ours showing a reduced LV dilatation and stabilized cardiac function when biomaterials such as porous, solvent-casted or particle leached substrates of poly(glyocolic-co-caprolactone), poly(lactic-co-caprolactone) or polyurethane hydrogel matrices were implanted together with MSCs [9, 10, [48] [49] [50] or skeletal myoblasts [4, 51] .The main advantages of the current patch design rely on its mechanical integrity and its very thin nature necessary for an adequate positioning on the beating heart that remained stable for at least 4 weeks. Furthermore, characteristics of our matrix, such as a versatile and cost-efficient production and functionalization technology, as well as high potential for custom-tailored and tissue-specific modification, guarantee straightforward scaling up of the biograft. Pilot plants of electrospinning devices as well as plasma polymerization reactors are commercially available and pave the way to a successful transfer to industry. The importance of MSCs for treatment efficacy has been underlined in this study. In parallel acellular patches provided no beneficial effect. The study, however, also presents certain limitations. Cell tracking, viability and potential differentiation 4 weeks post-implantation remain to be addressed in future studies. A mechanistic approach including evaluation of cell therapy on cardiac metabolism will also be investigated and will be necessary to move towards efficient and fine-tuned clinical application.
Conclusion
We provide evidence for a beneficial effect of an MSC-seeded plasma-coated PCL graft on cardiac function in a rodent model of MI. Importantly, we demonstrated that the designed patch presents adequate chemical properties and mechanical integrity to allow epicardial implantation and cell delivery without signs of Figure 7 . Goldner stained transversal heart sections. In blue, the fibrotic scar tissue is apparent, whereas the brown colour represents the remote tissue. The epicardially implanted patch is visible at the bottom of the image. Representative images of (A) MSCP, (B) CP and (C) sham treated animals. Scale bar: 5 mm and 100 lm, respectively. Table 2 Parameters of LV geometry, assessed based on colour recognition on Goldner stained cryosections. chronic inflammation. The optimized techniques of electrospinning and plasma polymerization allow for translational research and a potentially attractive transfer to the industry due to the use of convertible cost-effective procedures. Nevertheless, our findings warrant further thorough evaluation of the designed patch, particularly investigating the underlying mechanisms of cardiac repair.
